MIM
KNSA icon

MetLife Investment Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

MetLife Investment Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-22,695
Closed -$504K – 2882
2025
Q1 		$504K Sell
22,695
-400
-2% -$8.23K ﹤0.01% 1723
2024
Q4 		$457K Buy
23,095
+1,374
+6% +$31.4K ﹤0.01% 1851
2024
Q3 		$543K Buy
21,721
+12,239
+129% +$298K ﹤0.01% 1740
2024
Q2 		$177K Sell
9,482
-7,867
-45% -$147K ﹤0.01% 2323
2024
Q1 		$342K Hold
17,349
– – ﹤0.01% 1897
2023
Q4 		$304K Buy
+17,349
New +$285K ﹤0.01% 1989
2023
Q3 		– Sell
-17,349
Closed -$244K – 2934
2023
Q2 		$244K Hold
17,349
– – ﹤0.01% 2152
2023
Q1 		$187K Hold
17,349
– – ﹤0.01% 2265
2022
Q4 		$260K Hold
17,349
– – ﹤0.01% 2082
2022
Q3 		$223K Hold
17,349
– – ﹤0.01% 2227
2022
Q2 		$168K Hold
17,349
– – ﹤0.01% 2436
2022
Q1 		$172K Buy
17,349
+6,262
+56% +$66.3K ﹤0.01% 2446
2021
Q4 		$130K Hold
11,087
– – ﹤0.01% 2305
2021
Q3 		$126K Hold
11,087
– – ﹤0.01% 2339
2021
Q2 		$154K Hold
11,087
– – ﹤0.01% 2311
2021
Q1 		$205K Sell
11,087
-1,203
-10% -$24.6K ﹤0.01% 2039
2020
Q4 		$217K Hold
12,290
– – ﹤0.01% 1942
2020
Q3 		$188K Buy
12,290
+3,287
+37% +$61.7K ﹤0.01% 1898
2020
Q2 		$229K Buy
9,003
+1,911
+27% +$39.9K ﹤0.01% 1824
2020
Q1 		$110K Buy
+7,092
New +$111K ﹤0.01% 2019

Other funds holding KNSA

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

MetLife Investment Management's KNSA Position: Q2 2025 in Review

MetLife Investment Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2025, closing a stake of 22,695 shares — an estimated $504K sold.

MetLife Investment Management first reported a position in KNSA in Q1 2020 and held it in 20 quarters. The position peaked at $543K in Q3 2024. 189 funds tracked by Wall St. Rank hold KNSA as of Q2 2025.

  • MetLife Investment Management reported no remaining Kiniksa Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • MetLife Investment Management sold 22,695 Kiniksa Pharmaceuticals shares in Q2 2025, an estimated $504K.
  • MetLife Investment Management first reported a position in Kiniksa Pharmaceuticals in Q1 2020 and held it in 20 quarters.
  • MetLife Investment Management's Kiniksa Pharmaceuticals position peaked at $543K in Q3 2024.
  • 189 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2025.

Based on MetLife Investment Management's 13F filing for Q2 2025, filed 13 Aug 2025.